Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Cetuximab and Radiotherapy in Head and Neck Cancer
NCT03051906Phase 2Unknown
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Start
- Jan 2018
- Primary completion
- Jan 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Azienda Ospedaliero-Universitaria Careggi. Status: unknown.
02
Drugs
durvalumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03051906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051906.